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Introduction
Macrophage activation syndrome (MAS) - is a severe life-
threatening hematological condition, complicated different
rheumatic diseases. MAS is characterized by uncontrolled
proliferation of T cells and macrophages, associated with
decreased natural killer (NK) cells and cytotoxic T cell
function due to mutations in perforin gene.
Objectives
The aim of our study was to evaluate early predictors asso-
ciated with fatal outcomes in pediatric rheumatic disease.
These clinical and biomarkers can be useful in the mea-
surement of severity MAS.
Methods
We have performed retrospective study. Medical charts of
children with definite MAS who were admitted to our
rheumatology department in 2005-2013 were reviewed.
We utilized the A.Ravelli criteria (2002) for detecting
MAS. We used the main characteristic clinical and labora-
torial markers of MAS only at the moment of MAS confir-
mation (± 3 days). The patients who developed MAS in
the terminal study (irreversible polyorganic damage) were
excluded. We evaluated demographic data, data related to
MAS. Also we calculated cutoff points for fatal outcomes
(ROC-analysis), performed analysis of sensitivity and spe-
cificity and identified predictors with Log-Rank analysis
and Kaplan-Meier survival curves.
Results
23 patients (9 boys and 14 girls) with SLE (n = 2), AAV
(n = 2), SJIA (n = 17) and virus-associated HLH (n = 2)
were included. Median age of MAS was 7.4 years (range:1.5
mo-16.8 y), median time between disease onset and MAS
onset 11,4 mo (range:0.4-93.6 mo) and median duration of
MAS episode 68 days (range:11-336 days). Fatal outcome
was in 4 patients (2 SLE, 1 AAV, 1SJIA).
The main predictors of fatal outcomes were: onset of
disease>10.15 years (OR = 42.4, p = 0.004) ongoing gluco-
corticosteroid treatment at the time of MAS onset (OR =
63.0, p = 0.008), flare or active course of background rheu-
matic disease (p = 0.015), low sodium Na≤132 mmol/l
(OR = 93.0, p = 0.001), no splenomegaly (p = 0.023), no
lymphadenopathy (OR = 16.0, p = 0.04), hemorrhagic syn-
drome (OR = 31.0, p = 0.015), central nervous system
involvement (p = 0.015), WBC < 2400 cells in μl (OR =
54.0, p = 0.0001), Prothrombin < 43% (OR = 29.0, p =
0.002) and ESR >56 mm/h (OR = 39.0, p = 0.0007).
Conclusion
We detected several clinical and laboratorial markers
which reflect the severity of MAS. Presence of these signs
at onset of MAS can early differentiate the prognostic
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